luzhang108

Shared posts

15 Mar 01:24

Neutrophils bearing adhesive polymer micropatches as a drug-free cancer immunotherapy

by Ninad Kumbhojkar
luzhang108

cell-nano

Nature Biomedical Engineering, Published online: 29 February 2024; doi:10.1038/s41551-024-01180-z

The intravenous injection of neutrophils bearing discoidal polymer microscale ‘patches’ on their surfaces reduces tumour burden in mice owing to the patch-induced polarization of the neutrophils towards an antitumour phenotype.
15 Mar 01:23

Severely polarized extracellular acidity around tumour cells

by Qiang Feng

Nature Biomedical Engineering, Published online: 04 March 2024; doi:10.1038/s41551-024-01178-7

Hydronium ions bordering cancer cells are highly concentrated into a small extracellular region, and in tumour tissue such severely polarized acidity correlates with the expression of monocarboxylate transporters and with the exclusion of cytotoxic T cells.
15 Mar 01:22

Universal STING mimic boosts antitumour immunity via preferential activation of tumour control signalling pathways

by Ying Wang
luzhang108

polymeric universal STING mimic

Nature Nanotechnology, Published online: 13 March 2024; doi:10.1038/s41565-024-01624-2

There is interest in STING for immunotherapy, but it suffers from adverse proinflammatory effects. Here, the authors report on a non-membrane-associated polymeric universal STING mimic which triggers pathways involved in tumour control over proinflammatory pathways, demonstrating application in vivo.
14 Mar 06:31

An ATPase-Mimicking MXene nanozyme pharmacologically breaks the ironclad defense system for ferroptosis cancer therapy

by Huan Wang

Biomaterials. 2024 Jun;307:122523. doi: 10.1016/j.biomaterials.2024.122523. Epub 2024 Feb 27.

ABSTRACT

Anticancer nanomedicines used for ferroptosis therapy generally rely on the direct delivery of Fenton catalysts to drive lipid peroxidation in cancer cells. However, the therapeutic efficacy is limited by the ferroptosis resistance caused by the intracellular anti-ferroptotic signals. Herein, we report the intrinsic ATPase-mimicking activity of a vanadium carbide MXene nanozyme (PVCMs) to pharmacologically modulate the nuclear factor erythroid 2-related factor 2 (Nrf2) program, which is the master anti-ferroptotic mediator in the ironclad defense system in triple-negative breast cancer (TNBC) cells. The PVCMs perform high ATPase-like activity that can effectively and selectively catalyze the dephosphorylation of ATP to generate ADP. Through a cascade mechanism initiated by falling energy status, PVCMs can powerfully hinder the Nrf2 program to selectively drive ferroptosis in TNBC cells in response to PVCMs-induced glutathione depletion. This study provides a paradigm for the use of pharmacologically active nanozymes to moderate specific cellular signals and elicit desirable pharmacological activities for therapeutic applications.

PMID:38432004 | DOI:10.1016/j.biomaterials.2024.122523